Chemed Corporation
NYSE•CHE
CEO: Mr. Kevin J. McNamara
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1973-05-03
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Contact Information
255 East Fifth Street, Suite 2600, Cincinnati, OH, 45202-4726, United States
513-762-6690
Market Cap
$6.58B
P/E (TTM)
23.6
16.2
Dividend Yield
0.5%
52W High
$623.61
52W Low
$408.42
52W Range
Rank16Top 3.7%
6.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$624.90M+3.09%
4-Quarter Trend
EPS
$4.46-11.51%
4-Quarter Trend
FCF
$66.03M-14.22%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Consolidated Revenue Growth Service revenues reached $1.89B for nine months, reflecting 5.5% growth, primarily driven by VITAS segment performance.
VITAS Segment Leads Growth VITAS revenue increased 8.2% to $1.21B, supported by 6.6% rise in days-of-care and 3.8% reimbursement rate increase.
Strong Liquidity Maintained Company maintains satisfactory liquidity with $404.5M of unused lines of credit available under the revolving credit facility.
Share Repurchase Authorization Board authorized additional $300.0M for repurchases; $301.8M authorization remains available under the current plan.
Risk Factors
VITAS Medicare Cap Pressure VITAS gross margin declined due to $18.8M increase in Medicare Cap liability and higher variable patient care expenses.
Roto-Rooter Margin Compression Roto-Rooter gross margin fell to 50.2% due to increased variable expenses, including a $5.8M casualty insurance increase.
Cybersecurity Incident Impact VITAS experienced a data breach involving PHI; investigation ongoing regarding full scope and potential regulatory notification requirements.
Consolidated Net Income Nine-month net income declined to $188.5M from $211.7M, impacted by lower operating income and increased liabilities.
Outlook
Future Cost Management Evaluating pricing actions and cost savings efforts for fiscal year 2026 planning amid ongoing economic pressures and inflation.
Debt Covenant Compliance Management anticipates remaining in compliance with all quarterly financial covenants throughout the foreseeable future period.
Capital Deployment Strategy Continually evaluating capital utilization alternatives including share repurchase, debt repurchase, and potential acquisition opportunities.
New Tax Disclosure Finalized Finalizing impact analysis for ASU 2023-09 Income Tax Disclosure, expecting incorporation into future Annual Report footnotes.
Peer Comparison
Revenue (TTM)
$16.99B
EHC$5.80B
$5.37B
Gross Margin (Latest Quarter)
ACHC96.4%
90.8%
EHAB48.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| UHS | $12.89B | 9.4 | 19.9% | 33.3% |
| ENSG | $10.46B | 31.6 | 16.6% | 41.3% |
| EHC | $10.11B | 18.7 | 24.4% | 38.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.8%
Flat Growth
4Q Net Income CAGR
-10.7%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 25, 2026
EPS:$7.02
|Revenue:$658.97M
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 31, 2025|Revenue: $624.90M+3.1%|EPS: $4.46-11.5%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 31, 2025|Revenue: $618.80M+3.8%|EPS: $3.60-23.4%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: Apr 28, 2025|Revenue: $646.94M+9.8%|EPS: $4.91+14.2%MissForm 10-K/A - FY 2024
Period End: Dec 31, 2024|Filed: Apr 1, 2025|Revenue: $2.43B+7.4%|EPS: $20.10+11.0%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 28, 2025|Refer to amended dataForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 1, 2024|Revenue: $606.18M+7.4%|EPS: $5.04+1.4%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 26, 2024|Revenue: $595.88M+7.6%|EPS: $4.70+32.8%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: Apr 29, 2024|Revenue: $589.23M+5.2%|EPS: $4.30+18.8%Miss